ABBV vs. AZN, NVS, ABT, LLY, JNJ, MRK, PFE, BMY, ZTS, and RPRX
Should you be buying AbbVie stock or one of its competitors? The main competitors of AbbVie include AstraZeneca (AZN), Novartis (NVS), Abbott Laboratories (ABT), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol-Myers Squibb (BMY), Zoetis (ZTS), and Royalty Pharma (RPRX). These companies are all part of the "pharmaceutical preparations" industry.
AstraZeneca (NASDAQ:AZN) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment.
AstraZeneca pays an annual dividend of $1.93 per share and has a dividend yield of 2.4%. AbbVie pays an annual dividend of $6.20 per share and has a dividend yield of 3.7%. AstraZeneca pays out 94.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AbbVie pays out 184.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AstraZeneca has increased its dividend for 1 consecutive years.
AstraZeneca has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500.
In the previous week, AbbVie had 12 more articles in the media than AstraZeneca. MarketBeat recorded 28 mentions for AbbVie and 16 mentions for AstraZeneca. AbbVie's average media sentiment score of 1.18 beat AstraZeneca's score of 0.72 indicating that AstraZeneca is being referred to more favorably in the media.
AstraZeneca currently has a consensus target price of $88.00, indicating a potential upside of 9.53%. AbbVie has a consensus target price of $178.21, indicating a potential upside of 5.85%. Given AbbVie's higher probable upside, equities analysts clearly believe AstraZeneca is more favorable than AbbVie.
AbbVie received 1247 more outperform votes than AstraZeneca when rated by MarketBeat users. Likewise, 73.12% of users gave AbbVie an outperform vote while only 58.95% of users gave AstraZeneca an outperform vote.
AstraZeneca has higher earnings, but lower revenue than AbbVie. AstraZeneca is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.
AstraZeneca has a net margin of 13.30% compared to AstraZeneca's net margin of 11.02%. AstraZeneca's return on equity of 179.47% beat AbbVie's return on equity.
20.4% of AstraZeneca shares are owned by institutional investors. Comparatively, 70.2% of AbbVie shares are owned by institutional investors. 0.3% of AbbVie shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
AbbVie beats AstraZeneca on 15 of the 21 factors compared between the two stocks.
Get AbbVie News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABBV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
